Lightcast raises £19.9m to commercialise Envisia benchtop using light‑controlled droplet assays
This article covers Lightcast, a Cambridge biotech startup, which has raised £19.9m in a growth funding round to accelerate commercialisation of its Envisia benchtop platform for functional single-cell analysis. The funding aims to support the startup’s planned 2026 commercial launch, expand its assay portfolio and enable wider early-access deployment with pharmaceutical and academic partners in antibody discovery, oncology and cell therapy development.
Lightcast, a Cambridge biotech startup, has raised £19.9m in a growth funding round to accelerate commercialisation of its Envisia benchtop platform for functional single-cell analysis — funding the company’s planned 2026 commercial launch, expanded assay portfolio and wider early-access deployment with pharma and academic partners.
Why it matters
The funding signals continued investor interest in tools that move single-cell analysis from inference-based workflows toward direct functional measurement. By backing a benchtop system, investors are betting on broader accessibility for workflows used in antibody discovery, cell therapy development and functional biology, rather than restricting such capabilities to specialist facilities.
Inside the product
Envisia is a benchtop platform that interrogates tens of thousands of picoliter droplets using Lightcast’s light-controlled droplet manipulation technology. Rather than inferring cellular function from genomic or transcriptomic data, the platform captures direct functional readouts at single-cell resolution and supports sequential, highly controlled assays. Lightcast says the full commercial workflow will include instrumentation, intelligent software, a purpose-built cartridge system and assay kits optimised for different cell types and applications.
The company has been running an early access programme with pharmaceutical and academic groups to validate performance, refine workflows and expand applications across antibody discovery, oncology and cell-cell interaction studies. Lightcast was founded in 2019 and is based in Cambridge.
Who are the investors?
The round was led by ARCH Venture Partners, with participation from M Ventures, Illumina Ventures, +ND Capital, Longwall Ventures and OMX Ventures. The financing comes entirely from existing investors.
In the announcement, Sean Kendall, partner at ARCH Venture Partners, said:
Lightcast’s early commercial traction underscores the strength of its platform and the size of the opportunity ahead. We are increasing our investment because the Envisia platform addresses a clear gap in the market, bringing real-time, function-focused cellular analysis out of specialized labs and onto the benchtop, where it can significantly accelerate antibody discovery, oncology therapeutics, and cell line development and production.
The investor rationale focuses on moving functional cellular assays into more routine laboratory settings, shortening discovery cycles for therapeutics and enabling broader adoption by industry and translational research groups.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Paul Loeffen, PhD, CEO of Lightcast, said:
Single-cell analysis technologies have transformed how we characterize cells, but they have not fully captured how they behave. Our Envisia platform was built to deliver deep functional cellular insights. This financing is a strong validation of both our technology and the momentum we are seeing with customers, and it will enable us to deliver a commercial platform that can meaningfully accelerate how new therapies are discovered and developed.
To support the commercial push, Lightcast has appointed Brad Crutchfield — formerly chief commercial officer at 10x Genomics and adviser or board member to Mission Bio, Broken String Biosciences, Partillion Bioscience, Pixelgen Technologies and Alamar Biosciences — as an advisor to the board. In the announcement, Brad Crutchfield, advisor to Lightcast, said:
The Envisia platform represents an important evolution in single-cell analysis, enabling researchers to move beyond inference and directly measure function at the level of individual cells. Platforms that deliver this kind of insight have the potential to significantly accelerate discovery and reshape how new therapies are developed. I’m excited to support Lightcast as it brings this capability to a broad set of customers around the world.
The bigger picture
The deal reflects growing demand among biotech investors for instruments and workflows that reduce dependency on highly specialised facilities and shorten translational timelines. Commercialising functional single-cell assays on a benchtop platform could change how discovery teams evaluate candidates in antibody discovery and cell therapy, and it sits alongside a broader trend of funding into tools that enable applied, high-throughput biology.
Lightcast’s timeline to a 2026 commercial release will be watched by UK and European research groups and companies investing in next-generation drug discovery tools; successful scale-up would strengthen the region’s position in single-cell and functional assay technologies and could prompt further capital flows into similar instrument-focused ventures.
They've invested in Lightcast
Get to know these biotech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 ARCH Venture Partners | 1 investment investment | more info | |||
 M Ventures | 10 investments investments | 16 contacts contacts | |||
 Illumina Ventures | 3 investments investments | 8 contacts contacts | |||
 +ND Capital | 2 investments investments | more info | |||
 Longwall Ventures | 3 investments investments | 5 contacts contacts | |||
 OMX Ventures | 2 investments investments | more info |
Click here for a full list of 7,526+ startup investors in the UK